
News|Articles|November 1, 2026
FAQ: Diabetic eye disease awareness month 2026
Author(s)Kassi Filkins
An estimated 9.6 million people in the US have diabetic retinopathy, and roughly 1 in 3 patients with diabetes miss annual eye exams as AI screening and new therapies reshape care.
Advertisement
Advertisement
Prevent Blindness designates November as Diabetes-related Eye Disease Month.1 The 2026 observance arrives as an estimated 9.6 million people in the US live with diabetic retinopathy (DR), including 1.84 million with vision-threatening DR (VTDR).2,3 The questions below cover the screening gap, guideline updates, and recent trial data across DR and diabetic macular edema (DME).
Related to this article

Katherine Talcott, MD, discusses phase 2 VERONA findings on the vorolanib intravitreal insert in previously treated DME.

James Deom, OD, MPH, FAAO, FSLS, of Hazleton Eye Specialists, explains his baseline imaging approach, his nocturnal hypotension hypothesis and his same-day workup for patients on GLP-1 RAs who have sudden vision loss.

A longer axial length in the fellow eye of that treated for a rhegmatogenous retinal detachment was associated with a greater risk of a total retinal detachment.

Veeral S. Sheth, MD, MBA, FACS, FASRS, discusses the evidence behind the new labeling requirement and how it aligns with the AAO/NANOS consensus statement.

Josef Huemer, MD, discusses retinal changes linked to atrial fibrillation and what they mean for eye care clinicians.

The FDA adds a NAION warning to GLP-1 drugs, plus LEMS clues, Eyedaptic's new Eva AI assistant and a retinal imaging link to AFib.

The first-in-human study of the GalNAc-conjugated siRNA joins a fast-moving Stargardt pipeline as the FDA weighs the first potential approval for the disease.
Advertisement
Advertisement

